Skip to main content
SpringerLink
Log in

Aqueous prostaglandin E2 of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Ketorolac 0.4% administered four times daily (q.i.d.) has long been used safely and effectively for the alleviation of ocular inflamation and pain and the prevention of intraoperative miosis in patients undergoing cataract surgery. Bromfenac ophthalmic solution 0.09% was recently developed as an ocular anti-inflammatory drug with a twice-daily (b.i.d.) dosing regimen. This study was designed to evaluate if b.i.d. dosing with bromfenac 0.09%, in comparison with q.i.d. dosing with ketorolac 0.4%, provides adequate trough nonsteroidal anti-inflammatory drug levels that were effective enough to reduce aqueous prostaglandin (PG) E2 levels of patients after cataract surgery toward the end of its dosing cycle.

Methods

In this single-center, investigator-masked trial, patients undergoing cataract surgery were randomized to receive either ketorolac 0.4% q.i.d. or bromfenac 0.09% b.i.d. for 2 days preoperatively. Aqueous humor was collected at the start of surgery 6 hours after the last dose of ketorolac 0.4% and 12 hours after the last dose of bromfenac 0.09%. Aqueous PGE2 levels and drug concentrations were evaluated by a competitive enzyme immunoassay and reverse-phase HPLC-mass spectroscopy, respectively.

Results

A total of 61 patients received ketorolac 0.4% (n=30) or bromfenac 0.09% (n=31). The mean (±SD) aqueous PGE2 level was 285.6±141.9 pg/mL in patients treated with ketorolac 0.4% and 386.2±131.0 pg/mL in patients treated with bromfenac 0.09% (P=0.006). The mean (±SD) aqueous concentrations of ketorolac and bromfenac were 83.6±73.8 ng/mL and 9.2±6.6 ng/mL, respectively (P<0.001).

Conclusions

Ketorolac 0.4% maintained significantly higher aqueous concentrations and lowered aqueous PGE2 levels significantly more than bromfenac 0.09% at trough levels. Ketorolac 0.4% administered q.i.d. may provide a more sustained control of intraocular inflammation and pain than bromfenac 0.09% administered b.i.d.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Colin J. The role of NSAIDs in the management of postoperative ophthalmic inflammation. Drugs. 2007;67:1291–1308.

    Article  PubMed  CAS  Google Scholar 

  2. Heier J, Cheetham JK, Degryse R et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial. Am J Ophthalmol. 1999;127:253–259.

    Article  PubMed  CAS  Google Scholar 

  3. Holzer MP, Solomon KD, Sandoval HP, Vroman DT. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study. J Cataract Refract Surg. 2002;28:93–99.

    Article  PubMed  Google Scholar 

  4. Rajpal RK, Cooperman BB. Analgesic efficacy and safety of ketorolac after photorefractive keratectomy. Ketorolac Study Group. J Refract Surg. 1999;15:661–667.

    CAS  Google Scholar 

  5. Solomon KD, Vroman DT, Barker D, Gehlken J. Comparison of ketorolac tromethamine 0.5% and rimexolone 1% to control inflammation after cataract extraction. Prospective randomized double-masked study. J Cataract Refract Surg. 2001;27:1232–1237.

    Article  PubMed  CAS  Google Scholar 

  6. Perry HD, Donnenfeld ED. An update on the use of ophthalmic ketorolac tromethamine 0.4%. Expert Opin Pharmacother. 2006;7:99–107.

    Article  PubMed  CAS  Google Scholar 

  7. Donnenfeld ED, Perry HD, Wittpenn JR, Solomon R, Nattis A, Chou T. Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve. J Cataract Refract Surg. 2006;32:1474–1482.

    Article  PubMed  Google Scholar 

  8. Price FW, Jr., Price MO, Zeh W, Dobbins K. Pain reduction after laser in situ keratomileusis with ketorolac tromethamine ophthalmic solution 0.5%: a randomized, double-masked, placebocontrolled trial. J Refract Surg. 2002;18:140–144.

    PubMed  Google Scholar 

  9. Price MO, Price FW. Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Curr Med Res Opin. 2004;20:2015–2019.

    Article  PubMed  CAS  Google Scholar 

  10. Sandoval HP, Férnandez De Castro LE, Vroman DT, Solomon KD. Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation. J Ocul Pharmacol Ther. 2006;22:251–257.

    Article  PubMed  CAS  Google Scholar 

  11. Solomon KD, Donnenfeld ED, Raizman M et al. Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients. J Cataract Refract Surg. 2004;30:1653–1660.

    Article  PubMed  Google Scholar 

  12. Wittpenn JR, Silverstein S, Heier J et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol. 2008;146:554–560.

    Article  PubMed  CAS  Google Scholar 

  13. Xibrom [package insert]. Irvine, CA, USA: ISTA Pharmaceuticals, Inc.; 2006.

  14. Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR, Bromfenac OPhthalmic Solution (Xibrom) Study Group. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. Ophthalmology. 2007;114:1653–1662.

    Article  PubMed  Google Scholar 

  15. Acular LS [package insert]. Irvine, CA, USA: Allergan, Inc.; 2003.

  16. Koay P. The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology. Br J Ophthalmol. 1996;80:480–485.

    Article  PubMed  CAS  Google Scholar 

  17. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004;18:790–804.

    Article  PubMed  CAS  Google Scholar 

  18. Bucci FA Jr., Waterbury LD. Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels. J Cataract Refract Surg. 2008;34:1509–1512.

    Article  PubMed  Google Scholar 

  19. Decroos FC, Afshari NA. Perioperative antibiotics and anti-inflammatory agents in cataract surgery. Curr Opin Ophthalmol. 2008;19:22–26.

    Article  PubMed  Google Scholar 

  20. Bucci FA Jr., Waterbury LD, Amico LM. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (Acular LS) and nepafenac 0.1% (Nevanac) in patients undergoing phacoemulsification. Am J Ophthalmol. 2007;144:146–147.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bucci Laser Vision Institute, 158 Wilkes-Barre Township Boulevard, Wilkes-Barre, PA, 18702, USA

    Frank A. Bucci Jr.

  2. Raven Biosolutions, San Carlos, California, USA

    L. David Waterbury

Authors
  1. Frank A. Bucci Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. David Waterbury
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank A. Bucci Jr..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bucci, F.A., Waterbury, L.D. Aqueous prostaglandin E2 of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing. Adv Therapy 26, 645–650 (2009). https://doi.org/10.1007/s12325-009-0042-5

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-009-0042-5

Keywords

Search

Navigation